Treatment of the negative symptoms of schizophrenia with (R) -7-chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
(R) -7-Chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising said (R) -7-chloro- N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide or pharmaceutically acceptable salt thereof, for use in a method of treating an individual suffering from negative symptoms of schizophrenia, where the (R) -5 7-Chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide or a pharmaceutically acceptable salt thereof is administered to the patient in a daily dose of 0.1 mg - 3 mg.(R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma, o una composición farmacéutica que comprende dicha (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida o sal farmacéuticamente aceptable de la misma, para el uso en un método de tratamiento de un individuo que sufre síntomas negativos de esquizofrenia, en donde la (R)-5 7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma se administra al paciente en un dosis diaria de 0,1 mg - 3 mg.
